Klinger joined the Cambridge, Massachusetts-based pharmaceutical company in 2021, when Moderna's stock was trading at around ...

Moderna (MRNA) has disclosed a new risk, in the Sales & Marketing category. See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and streamline your search ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8522 ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 3103.07 with a total volume of 1,821.00. In the following chart, we are able to follow the development of ...

Moderna reports larger-than-expected quarterly loss Revenue falls 66% but beats expectations FDA pauses norovirus vaccine trial after adverse event report Feb 14 (Reuters) - Moderna (MRNA.O ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 vaccine sales.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.

A year earlier, Moderna earned $217 million, or 55 cents a share. The company's fourth-quarter sales slid 65% to $966 million, above analysts’ expectations.. Shares rose almost 3% Friday afternoon.

Moderna recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent ...

Genevant Sciences and Arbutus Biopharma (ABUS) filed five international lawsuits seeking to enforce patents protecting their innovative LNP ...